Paola A Gehrig

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Promising novel therapies for the treatment of endometrial cancer
    Paola A Gehrig
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7572, USA
    Gynecol Oncol 116:187-94. 2010
  2. ncbi request reprint What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?
    Paola A Gehrig
    Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Gynecol Oncol 111:41-5. 2008
  3. ncbi request reprint The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 107:285-91. 2007
  4. ncbi request reprint An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
  5. ncbi request reprint The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance
    Emily M Ko
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, USA University of North Carolina Lineberger Comprehensive Cancer Center, USA Electronic address
    Gynecol Oncol 133:28-32. 2014
  6. ncbi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
  7. ncbi request reprint Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
    Gynecol Oncol 114:279-83. 2009
  8. pmc Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
    Aaron Shafer
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599 7572, USA
    Int J Cancer 126:1144-54. 2010
  9. pmc Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
    Rabbie K Hanna
    University of North Carolina, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chapel Hill, NC, USA
    Gynecol Oncol 125:458-69. 2012
  10. ncbi request reprint A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy
    John F Boggess
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Am J Obstet Gynecol 199:360.e1-9. 2008

Collaborators

Detail Information

Publications59

  1. ncbi request reprint Promising novel therapies for the treatment of endometrial cancer
    Paola A Gehrig
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7572, USA
    Gynecol Oncol 116:187-94. 2010
    ..While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who suffer from a disease recurrence are limited and there is a need to identify novel agents...
  2. ncbi request reprint What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?
    Paola A Gehrig
    Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Gynecol Oncol 111:41-5. 2008
    ..We sought to compare minimally invasive surgical techniques for staging the obese and morbidly obese woman with endometrial cancer...
  3. ncbi request reprint The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer
    Angeles Alvarez Secord
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 107:285-91. 2007
    ..We sought to determine the outcome of patients with advanced stage endometrial cancer treated with postoperative chemotherapy+/-radiation to determine whether there was an advantage to combining treatment modalities...
  4. ncbi request reprint An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
    Gynecol Oncol 115:244-8. 2009
    ..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC...
  5. ncbi request reprint The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance
    Emily M Ko
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, USA University of North Carolina Lineberger Comprehensive Cancer Center, USA Electronic address
    Gynecol Oncol 133:28-32. 2014
    ..We examined the distribution of obesity, diabetes, and race in Type I and Type II endometrial cancers (EC) and their associations with clinical outcomes...
  6. ncbi request reprint Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
    Gynecol Oncol 112:558-62. 2009
    ..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)...
  7. ncbi request reprint Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
    Gynecol Oncol 114:279-83. 2009
    ..To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease...
  8. pmc Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
    Aaron Shafer
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599 7572, USA
    Int J Cancer 126:1144-54. 2010
    ..This suggests that the combination of rapamycin and paclitaxel may be a promising effective targeted therapy for endometrial cancer...
  9. pmc Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
    Rabbie K Hanna
    University of North Carolina, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chapel Hill, NC, USA
    Gynecol Oncol 125:458-69. 2012
    ..To examine the effects of combination therapy with metformin and paclitaxel in endometrial cancer cell lines...
  10. ncbi request reprint A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy
    John F Boggess
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
    Am J Obstet Gynecol 199:360.e1-9. 2008
    ..The purpose of this study was to compare outcomes in women who underwent endometrial cancer staging by different surgical techniques...
  11. ncbi request reprint Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
    Victoria L Bae-Jump
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7570, Chapel Hill, NC 27599, USA
    Gynecol Oncol 100:487-94. 2006
    ..Our goal was to examine the ability of rapamycin to suppress growth and regulate telomerase activity in cervical and ovarian cancer cell lines...
  12. ncbi request reprint Synergistic effect of rapamycin and cisplatin in endometrial cancer cells
    Victoria L Bae-Jump
    Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA
    Cancer 115:3887-96. 2009
    ..Because rapamycin is known to enhance the cytotoxicity of chemotherapeutic drugs, the authors' goal was to examine the effects of rapamycin and cisplatin in endometrial cancer cell lines...
  13. ncbi request reprint Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment
    Victoria L Bae-Jump
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Gynecol Oncol 119:579-85. 2010
    ..Our goal was to evaluate the effect of rapamycin, an mTOR inhibitor, in type I and II human endometrial cancer tumor explants...
  14. ncbi request reprint Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up
    Elizabeth N Skinner
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC 27599, USA
    Gynecol Oncol 98:59-62. 2005
    ..To determine the impact of weekly paclitaxel consolidation on progression-free survival (PFS) of women undergoing treatment for ovarian cancer...
  15. pmc Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy
    Leigh A Cantrell
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, CB 7572, Chapel Hill, NC 27599 7572, USA
    Gynecol Oncol 116:92-8. 2010
    ..In order to better understand metformin's anti-tumorigenic potential, our goal was to assess the effect of metformin on proliferation and expression of key targets of metformin cell signaling in endometrial cancer cell lines...
  16. ncbi request reprint Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experience
    Leigh A Cantrell
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC 27599 7572, USA
    Gynecol Oncol 117:260-5. 2010
    ..Longer follow-up is needed, but early data are supportive of at least equivalent oncologic outcomes compared with other surgical modalities...
  17. ncbi request reprint Metformin is associated with improved survival in endometrial cancer
    Emily M Ko
    University of Pennsylvania, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, USA
    Gynecol Oncol 132:438-42. 2014
    ..Preclinical evidence suggests that metformin exhibits anti-tumorigenic effects in endometrial cancer. We sought to investigate the association of metformin on endometrial cancer outcomes...
  18. ncbi request reprint Outcomes in surgical stage I uterine papillary serous carcinoma
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 105:677-82. 2007
    ..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy...
  19. ncbi request reprint The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels
    Chunxiao Zhou
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB 7570, Chapel Hill, NC 27599, USA
    Gynecol Oncol 101:305-10. 2006
    ..Given that PTEN is often absent and telomerase is overexpressed by endometrial cancers, we hypothesize that PTEN signaling is important in telomerase regulation...
  20. ncbi request reprint A case-control study of robot-assisted type III radical hysterectomy with pelvic lymph node dissection compared with open radical hysterectomy
    John F Boggess
    Division of Gynecology Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Am J Obstet Gynecol 199:357.e1-7. 2008
    ..The purpose of this study was to compare robotically assisted hysterectomy (RAH) with open (ORH) type III radical hysterectomy in the treatment of early-stage cervical cancer...
  21. ncbi request reprint Perioperative outcomes of robotically assisted hysterectomy for benign cases with complex pathology
    John F Boggess
    Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Obstet Gynecol 114:585-93. 2009
    ..To report on the perioperative outcomes after robotically assisted total hysterectomy for benign indications in a large patient population with predominantly complex pathology...
  22. ncbi request reprint Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    David M Boruta
    Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599, USA
    Cancer 101:2214-21. 2004
    ....
  23. doi request reprint Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients
    Emily M Ko
    Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA Electronic address
    Gynecol Oncol 131:683-8. 2013
    ..However, limited information exists regarding the clinical risk factors of ovarian cancer patients who develop palmar plantar erythrodysesthesia (PPE) while receiving PLD for cancer recurrence...
  24. pmc Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cells
    Chunxiao Zhou
    Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA
    PLoS ONE 8:e55730. 2013
    ..These findings suggest that E2-induction of telomerase activity is mediated via the MAPK pathway in human endometrial cancer cells...
  25. doi request reprint Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma
    Joshua E Kilgore
    Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA
    Gynecol Oncol 129:49-53. 2013
    ..The aim of this study is to report recurrence-free and overall survival for women with endometrial adenocarcinoma who were surgically staged using robotic-assisted laparoscopy...
  26. doi request reprint Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?
    William J Lowery
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 126:12-5. 2012
    ..We sought to evaluate the effect of systematic lymphadenectomy (LND) on endometrial cancer-specific survival in an elderly population...
  27. ncbi request reprint Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines
    John F Boggess
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Gynecol Oncol 103:417-24. 2006
    ....
  28. doi request reprint Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution review
    Michael R Milam
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Louisville Medical Center, Louisville, KY, USA
    Ann Surg Oncol 17:1106-10. 2010
    ..D. Anderson Cancer Center (MDACC) and the University of North Carolina (UNC)...
  29. doi request reprint Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer 115:2119-27. 2009
    ..A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients...
  30. ncbi request reprint Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells
    Victoria L Bae-Jump
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Reprod Sci 15:1011-7. 2008
    ..Thus, As(2)O(3) may be valuable for its anti-estrogenic activity in combination with its anti-tumorigenic effects and be a novel therapeutic agent for endometrial cancer...
  31. ncbi request reprint Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells
    Chunxiao Zhou
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, CB 7570 MacNider Building, Chapel Hill, NC 27599 7570, USA
    Gynecol Oncol 105:218-22. 2007
    ..To examine the effects of arsenic trioxide (As2O3) on human endometrial carcinoma cell lines with respect to cytotoxicity and the induction of apoptosis and telomerase expression in vitro...
  32. ncbi request reprint Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group
    Gregory Sutton
    St Vincent Hospitals and Health Services, Division of Gynecologic Oncology, 8301 Harcourt Road, Suite 202, Indianapolis, IN 46260, USA
    Gynecol Oncol 100:349-54. 2006
    ..To evaluate outcome in patients with clinical stage I/II papillary serous (PS) or clear cell (CC) endometrial carcinoma treated with whole abdominal radiotherapy...
  33. doi request reprint Outpatient end of life discussions shorten hospital admissions in gynecologic oncology patients
    Kemi M Doll
    Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, United States
    Gynecol Oncol 130:152-5. 2013
    ..The study goal was to determine whether prior outpatient exposure to hospice discussion altered the inpatient course and end-of-life (EOL) care among patients ultimately discharged to hospice...
  34. ncbi request reprint A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma
    Leigh A Cantrell
    Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Gynecol Oncol 127:22-6. 2012
    ..To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma...
  35. doi request reprint Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery
    Jason Franasiak
    Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
    Gynecol Oncol 126:437-42. 2012
    ..There is limited data regarding physical strain and minimally invasive gynecologic surgery (MIS). We sought to evaluate ergonomic strain among gynecologic oncologists...
  36. doi request reprint Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer
    Robin A Laskey
    Department of Obstetrics and Gynecology, Duke University Medical Center, USA
    Gynecol Oncol 125:625-30. 2012
    ..To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy...
  37. ncbi request reprint Association between uterine serous carcinoma and breast cancer
    Paola A Gehrig
    Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC 27599 7570, USA
    Gynecol Oncol 94:208-11. 2004
    ....
  38. ncbi request reprint Fertility-sparing surgery for ovarian low malignant potential tumors
    Gautam G Rao
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 98:263-6. 2005
    ..Conservative management usually involves leaving behind the uterus and contralateral adnexa to allow future childbearing. The purpose of this study was to determine the outcome of women treated with fertility-sparing surgery...
  39. ncbi request reprint Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix
    Shawna L Bull-Phelps
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390 9032, USA
    Gynecol Oncol 107:316-9. 2007
    ..The purpose of this study was to determine the outcomes of patients treated by this fertility-sparing strategy over an extended period of surveillance...
  40. pmc Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology
    Whitney P Caron
    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy W P C, P K, S E N, W C Z, School of Medicine J C L, A M F, D L C P, W R B, L V L, V L B J, P A G, Department of Biostatistics H Z, J H M, Lineberger Comprehensive Cancer Center D L C P, W R B, L V L, V L B J, P A G, W C Z, Institute for Pharmacogenomics and Individualized Therapy W C Z, Carolina Center of Cancer Nanotechnology Excellence W C Z, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina School of Pharmacy, Texas Tech University Health Sciences Center, St Amarillo, Texas N M L B and North Carolina Biomedical Innovation Network, Research Triangle Park, North Carolina W C Z
    J Pharmacol Exp Ther 347:599-606. 2013
    ..43, P = 0.04) and ROS production (R(2) = 0.61, P = 0.008) in blood MO/DC. These findings suggest that probes of MPS function may help predict PEGylated liposome CL across species and PLD CL in patients with EOC. ..
  41. doi request reprint Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors
    Jessica E Stine
    University of North Carolina at Chapel Hill, Division of Gynecologic Oncology, USA Electronic address
    Gynecol Oncol 131:59-62. 2013
    ..To determine the radiographic characteristics of ovarian granulosa cell tumors (GCTs) and to evaluate the use of CA125 levels >35 in combination with imaging as an algorithm for preoperative diagnosis...
  42. ncbi request reprint Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes
    Alberto Mendivil
    Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Cancer Control 16:46-52. 2009
    ..Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens...
  43. ncbi request reprint Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review
    David M Boruta
    Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 115:142-53. 2009
    ..This review summarizes the available literature concerning UPSC in an effort to provide the clinician with information pertinent to its management...
  44. doi request reprint High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes
    Kemi M Doll
    Division of Gynecologic Oncology, University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA Electronic address
    Gynecol Oncol 132:44-9. 2014
    ..Data in patients with high-grade histology are limited. Our goal is to determine if TS or lower uterine segment (LUS) involvement, is associated with nodal disease and recurrence in women with high-grade endometrial cancer...
  45. ncbi request reprint Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma
    Jessica L Hubbs
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7572, USA
    Obstet Gynecol 121:1172-80. 2013
    ..To estimate disease regression, persistence, and progression in women with complex endometrial hyperplasia and stage I endometrial carcinoma treated with a levonorgestrel-releasing-intrauterine system or oral progesterone...
  46. doi request reprint Management of a persistent adnexal mass in pregnancy: what is the ideal surgical approach?
    Ursula Balthazar
    Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
    J Minim Invasive Gynecol 18:720-5. 2011
    ..To compare short-term and pregnancy-related outcomes of laparoscopy with laparotomy for management of a persistent second-trimester adnexal mass...
  47. ncbi request reprint Surgical staging of ovarian low malignant potential tumors
    Gautam G Rao
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Obstet Gynecol 104:261-6. 2004
    ..The purpose of this study was to compare the outcome of surgically staged patients with low malignant potential tumors with those who were not staged...
  48. ncbi request reprint Extraskeletal myxoid chondrosarcoma: a report of a gynecologic case
    Mildred R Santacruz
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, 4013 B Old Clinic Building, Chapel Hill, NC 27599, USA
    Gynecol Oncol 98:498-501. 2005
    ..Extraskeletal myxoid chondrosarcoma is a rare tumor that has been reported and discussed in neurosurgical, orthopedic, and otolaryngologic literature. We report a case of vulvar extraskeletal myxoid chondrosarcoma...
  49. ncbi request reprint Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer
    Monica N Schointuch
    Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC, USA
    Gynecol Oncol 134:346-55. 2014
    ..Our goal was to evaluate the effects of simvastatin on endometrial cancer cell lines and primary cultures of endometrial cancer cells...
  50. ncbi request reprint Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer
    Rebecca Ann Previs
    Division of Gynecologic Oncology, Duke Cancer Institute, Duke University Medical Center, Durham University of North Carolina School of Medicine, Chapel Hill Department of Pathology, Duke University Medical Center, Durham and Department of Pathology and Laboratory Medicine and Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC
    Int J Gynecol Cancer 24:670-5. 2014
    ..The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC)...
  51. doi request reprint Factors associated with an increased risk of recurrence in women with ovarian granulosa cell tumors
    Anuj Suri
    Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, NC, USA
    Gynecol Oncol 131:321-4. 2013
    ..The goal of this study is to determine demographic and prognostic factors affecting disease recurrence in women with early stage ovarian granulosa cell tumors (GCT)...
  52. doi request reprint Early stage uterine serous carcinoma: management updates and genomic advances
    Amanda Nickles Fader
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Gynecol Oncol 129:244-50. 2013
    ..Prospective data to guide therapy for women with this disease are limited. This article reviews the currently available literature regarding optimal management of women with early stage USC...
  53. ncbi request reprint Uterine papillary serous carcinoma: a review
    Paola A Gehrig
    University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, CB 7570 MacNider Building, Chapel Hill, NC 27599 7570, USA
    Expert Opin Pharmacother 8:809-16. 2007
    ..There is a need for clinical trials to determine the optimal therapy for this cohort of patients...
  54. ncbi request reprint The role of optimal debulking in advanced stage serous carcinoma of the uterus
    Karen A Moller
    UNC Chapel Hill, CB7570, Chapel Hill, NC 27599, USA
    Gynecol Oncol 94:170-4. 2004
    ..To evaluate the role of optimal surgical cytoreduction and postoperative therapy in women with advanced uterine serous carcinoma (USC)...
  55. ncbi request reprint High-grade squamous intraepithelial lesions: abbreviating posttreatment surveillance
    Elizabeth N Skinner
    Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina Chapel Hill, CB 7570 Women s Hospital, Chapel Hill, NC 27599, USA
    Obstet Gynecol 103:488-92. 2004
    ..To evaluate whether the surveillance schedule for patients treated with loop excision for high-grade squamous intraepithelial lesions could be improved...
  56. doi request reprint Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
    Ninh M La-Beck
    UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Cancer Chemother Pharmacol 69:43-50. 2012
    ..We previously reported that age, gender, body composition, and monocytes affect the clearance of other liposomal agents. Therefore, we evaluated how these factors affect the pharmacokinetics of PLD...
  57. ncbi request reprint Weekly paclitaxel infusion as salvage therapy in ovarian cancer
    David M Boruta
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Campus Box 7570, 4013 Old Clinic Building, Chapel Hill, NC 27599 7570, USA
    Cancer Invest 21:675-81. 2003
    ..The regimen is well tolerated with no cases of grade 4 neutropenia or worsening neuropathy in our population...
  58. ncbi request reprint Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells
    Chunxiao Zhou
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Cancer Ther 2:789-95. 2003
    ..This work suggests that rapamycin is a potentially useful targeted therapy for endometrial cancer and that loss of telomerase activity may be a good surrogate biomarker for assessing antitumor activity of rapamycin...
  59. ncbi request reprint Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ
    Jayanthi S Lea
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    Gynecol Oncol 87:129-32. 2002
    ..To determine if performing an endocervical curettage (ECC) at the time of conization is a useful diagnostic tool for predicting residual cervical adenocarcinoma in situ (AIS) among women who might wish to preserve their fertility...